Drug Profile
Research programme: CD40/FasL fusion protein - KAHR Medical
Alternative Names: KAHR-103Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator KAHR Medical
- Class Proteins
- Mechanism of Action CD40 antigen stimulants; CD95 antigen stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Israel